Xolair Pediatric (Ages 6-11) BLA Extension Must Overcome "Relatively Modest" Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA briefing materials for Nov. 18 advisory committee meeting note reductions in asthma exacerbations but few clinically meaningful benefits on secondary efficacy measures.